NEW YORK, NY — A new FDA approval has created a buzz inside biotechs involved with medical marijuana research. When Nuvilex, Inc. (OTCQB: NVLX) announced the formation of its new medical marijuana subsidiary, Medical Marijuana Sciences, Inc., the company’s CEO, Dr. Robert Ryan, said then that its research would focus initially on cannabidiol (CBD), one of the compounds found in Cannabis, as the basis for developing treatments for serious and deadly forms of cancer. Well, this month the U.S. Food and Drug Administration (FDA) apparently agreed that CBD is the way to go and they’ve approved clinical trials using the compound.